165 related articles for article (PubMed ID: 11194490)
1. [The use of erythropoietin alpha in programs of high-dose chemotherapy].
Danova M; Aglietta M; Pierelli L; Ferrari S; Perillo A; Scambia G; Henry D
Recenti Prog Med; 2000 Dec; 91(12):681-9. PubMed ID: 11194490
[TBL] [Abstract][Full Text] [Related]
2. Epoetin alfa and high-dose chemotherapy.
Henry DH
Semin Oncol; 1998 Jun; 25(3 Suppl 7):54-7. PubMed ID: 9671332
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with G-CSF and erythropoietin after autologous bone marrow transplantation for lymphoid malignancies: a randomized trial.
Vannucchi AM; Bosi A; Ieri A; Guidi S; Saccardi R; Lombardini L; Linari S; Laszlo D; Longo G; Rossi-Ferrini P
Bone Marrow Transplant; 1996 Apr; 17(4):527-31. PubMed ID: 8722349
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin in combination with other hematopoietic cytokines in attenuating chemotherapy-induced multilineage myelosuppression: brief communication.
Vadhan-Raj S
Semin Hematol; 1996 Jan; 33(1 Suppl 1):16-8. PubMed ID: 8714611
[No Abstract] [Full Text] [Related]
5. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach.
Mundle S; Lefebvre P; Vekeman F; Duh MS; Rastogi R; Moyo V
Cancer; 2009 Feb; 115(4):706-15. PubMed ID: 19152429
[TBL] [Abstract][Full Text] [Related]
6. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
7. Antianemic effect of once weekly regimen of epoetin alfa 40,000 units in anemic cancer patients receiving chemotherapy.
Voravud N; Sriuranpong V; Suwanrusme H
J Med Assoc Thai; 2007 Jun; 90(6):1082-8. PubMed ID: 17624200
[TBL] [Abstract][Full Text] [Related]
8. Detection and quantification of functionally defined hematopoietic progenitor cells and tissue specific mRNA within the peripheral blood of myeloma patients after administration of granulocyte colony-stimulating factor and erythropoietin.
Grassinger J; Mueller G; Hart C; Nilsson SK; Haylock DN; Andreesen R; Hennemann B
Eur J Haematol; 2008 Jan; 80(1):20-30. PubMed ID: 18028434
[TBL] [Abstract][Full Text] [Related]
9. Anemia and epoetin alfa in high-dose chemotherapy programs for breast cancer patients.
Danova M; Ferrari S
Semin Oncol; 2002 Jun; 29(3 Suppl 8):21-5. PubMed ID: 12082650
[TBL] [Abstract][Full Text] [Related]
10. Use of epoetin alfa in critically ill patients.
Pajoumand M; Erstad BL; Camamo JM
Ann Pharmacother; 2004 Apr; 38(4):641-8. PubMed ID: 14966258
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
12. Utilisation review of epoetin alfa in cancer patients at a cancer centre in Singapore.
Chan A; Lim LL; Tao M
Singapore Med J; 2009 Apr; 50(4):365-70. PubMed ID: 19421679
[TBL] [Abstract][Full Text] [Related]
13. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim.
Weaver CH; Schulman KA; Buckner CD
Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117
[TBL] [Abstract][Full Text] [Related]
14. Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes.
Casadevall N
Semin Oncol; 1998 Jun; 25(3 Suppl 7):12-8. PubMed ID: 9671324
[TBL] [Abstract][Full Text] [Related]
15. Advances in the clinical use of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor to intensify cancer chemotherapy.
Fisher DC; Peters WP
Curr Opin Hematol; 1994 May; 1(3):221-7. PubMed ID: 9371286
[TBL] [Abstract][Full Text] [Related]
16. Treatment of cancer-related anemia with epoetin alfa: a review.
Ferrario E; Ferrari L; Bidoli P; De Candis D; Del Vecchio M; De Dosso S; Buzzoni R; Bajetta E
Cancer Treat Rev; 2004 Oct; 30(6):563-75. PubMed ID: 15325036
[TBL] [Abstract][Full Text] [Related]
17. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
18. Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry.
de la Rubia J; de Arriba F; Arbona C; Pascual MJ; Zamora C; Insunza A; Martínez D; Paniagua C; Díaz MA; Sanz MA
Haematologica; 2008 May; 93(5):735-40. PubMed ID: 18387976
[TBL] [Abstract][Full Text] [Related]
19. GM-CSF versus G-CSF: engraftment characteristics, resource utilization, and cost following autologous PBSC transplantation.
Zumberg MS; Leather HL; Nejame C; Meyer C; Wingard JR
Cytotherapy; 2002; 4(6):531-8. PubMed ID: 12568989
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic growth factors for the treatment of myelodysplastic syndromes.
Hast R; Bernell P
Acta Haematol Pol; 1991; 22(2):203-7. PubMed ID: 1726768
[No Abstract] [Full Text] [Related]
[Next] [New Search]
